Tempus Stock

tempus.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $3.06B

Tempus is a biotechnology company that uses AI-driven precision medicine. By deriving insights from a library of clinical data and molecular data, Tempus has a mission to build personalized healthcare data to support diagnostics in cardiology, neuropsychiatry, radiology, and infectious diseases. The goal of Tempus is to help patients live longer lives, backed by machine learning tools and technology. Tempus was founded by Eric Lefkofsky in 2015 and is headquartered in Chicago, IL.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Tempus before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Tempus Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Tempus Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
04/30/2024 Series G-5 $200MM $xx.xx $8.89B Softbank
Price per Share
$xx.xx
Shares Outstanding
3,489,981
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.3%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Softbank
10/11/2023 Series G-4 $45.61MM $xx.xx $8.7B Scottish Mortgage Investment Trust
Price per Share
$xx.xx
Shares Outstanding
795,911
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.3%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Scottish Mortgage Investment Trust
10/03/2022 Series G-3 $99.05MM $xx.xx $8.45B Blue Media, Scottish Mortgage Investment Trust, The Schiehallion Fund
Price per Share
$xx.xx
Shares Outstanding
1,728,360
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
4.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Blue Media, Scottish Mortgage Investment Trust, The Schiehallion Fund
01/15/2021 Series G-2 $197.89MM $xx.xx $8.12B Baillie Gifford, Blue Media, Franklin Templeton, Google, Novo Holdings, Scottish Mortgage Investment Trust, The Schiehallion Fund, T. Rowe Price
Price per Share
$xx.xx
Shares Outstanding
3,453,139
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Baillie Gifford, Blue Media, Franklin Templeton, Google, Novo Holdings, Scottish Mortgage Investment Trust, The Schiehallion Fund, T. Rowe Price
03/13/2020 Series G $97.31MM $xx.xx $5B Baillie Gifford, Franklin Templeton Investments, New Enterprise Associates, Novo Holdings
Price per Share
$xx.xx
Shares Outstanding
2,537,290
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Baillie Gifford, Franklin Templeton Investments, New Enterprise Associates, Novo Holdings
05/30/2019 Series F $200MM $xx.xx $3.1B Baillie Gifford, Franklin Templeton Investments, New Enterprise Associates, Novo Holdings, Revolution Group, T.Rowe Price
Price per Share
$xx.xx
Shares Outstanding
8,077,674
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Baillie Gifford, Franklin Templeton Investments, New Enterprise Associates, Novo Holdings, Revolution Group, T.Rowe Price
08/23/2018 Series E $111.02MM $xx.xx $2B Baillie Gifford, New Enterprise Associates, Revolution, T. Rowe Price
Price per Share
$xx.xx
Shares Outstanding
6,630,905
Liquidation Pref Order
7
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Baillie Gifford, New Enterprise Associates, Revolution, T. Rowe Price
03/30/2018 Series D $80MM $xx.xx $1.03B Kinship Trust Company, New Enterprise Associates, Revolution, T.Rowe Price
Price per Share
$xx.xx
Shares Outstanding
8,534,330
Liquidation Pref Order
8
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Kinship Trust Company, New Enterprise Associates, Revolution, T.Rowe Price
09/25/2017 Series C $70MM $xx.xx $700MM New Enterprise Associates, Revolution
Price per Share
$xx.xx
Shares Outstanding
9,779,403
Liquidation Pref Order
9
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
--
Key Investors
New Enterprise Associates, Revolution
04/17/2017 Series B-2 $30MM $xx.xx $584.99MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
4,191,173
Liquidation Pref Order
10
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
11/22/2016 Series B-1 $10MM $xx.xx $286MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
2,500,000
Liquidation Pref Order
10
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
06/20/2016 Series B $10MM $xx.xx $143.02MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
5,374,899
Liquidation Pref Order
10
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
09/21/2015 Series A $10MM $xx.xx $66.67MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
10,000,000
Liquidation Pref Order
11
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Tempus Investors Also Invested in These Private Companies

Leadership & Board

Leadership

Kevin White, Ph.D.
Chief Science Officer
Vanessa Rollings
Chief Financial Officer
Eric Lefkofsky
Founder & Chief Executive Officer
Ryan Fukushima
Chief Operating Officer
Marc Yoskowitz
Chief Strategy Officer
Mike Yasiejko
Chief Commercial Officer
Gary Palmer, MD
Chief Medical Officer
Shane Colley
Chief Technology Officer
Chief Strategy Officer
Chief People Officer

Board

David Agus, MD
A. Keith Stewart, MB.CHB., MBA
Steve Case
Revolution
Arul M. Chinnaiyan, MD, Ph.D.
Peter Barris
New Enterprise Associates
Funmi Olopade, MD
Eric Topol, MD
John Doerr
Kleiner Perkins

Tempus stock FAQs

plusminus

Can you buy Tempus stock?

You can no longer buy Tempus stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Tempus stock?

You can no longer buy Tempus stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Tempus stock?

You can no longer sell stock of Tempus on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Tempus stock?

You can no longer sell stock of Tempus on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is Tempus a public company?

Tempus is now a public company traded on NASDAQ with ticker TEM.
plusminus

What is Tempus’ stock price?

The stock price of Tempus is not currently available.
plusminus

What is Tempus’ stock ticker symbol?

The ticker symbol of Tempus is TEM.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Tempus News and Media Highlights

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, "Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer," in JAMA Network Open. Tempus recently conducted a retrospective study of more than 5,500 patients with advanced non-small cell lung cancer (NSCLC) and found that concurrent RNA- and DNA-based next-generation sequencing (NGS) led to the detection of more actionable structural variants compared to DNA sequencing alone.

The cofounder of Groupon launched a cancer data startup after his wife's diagnosis. Now it's worth $2 billion after just three years

BI PRIME: Tempus, a Chicago-based startup that pulls together data on cancer patients on its platform, has grown in three years to a $2 billion valuation and has plans to expand beyond cancer.

Tempus Ramps Up AI-Driven Precision Oncology, Eyes Other Markets

After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.

REFILE-BRIEF-Shenzhen Exchange Filing Shows Block Trade Of Tempus...

(Refiles to fix formatting in headline)
Browse Insights
Updated on: Dec 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.